HomeGRAL • NASDAQ
Grail Inc
$14.40
Makalipas ang Oras ng Trabaho:
$14.40
(0.00%)0.00
Sarado: Set 27, 5:47:37 PM GMT-4 · USD · NASDAQ · Disclaimer
StockSegurong nakalista sa USMay headquarter sa US
Nakaraang pagsara
$13.60
Sakop ng araw
$13.54 - $14.43
Sakop ng taon
$13.41 - $21.47
Market cap
447.11M USD
Average na Volume
944.63K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
(USD)Hun 2024Y/Y na pagbabago
Kita
31.97M42.63%
Gastos sa pagpapatakbo
202.44M12.41%
Net na kita
-1.59B-721.23%
Net profit margin
-4.96K-475.76%
Kita sa bawat share
——
EBITDA
-180.97M-9.52%
Aktuwal na % ng binabayarang buwis
3.24%—
Kabuuang asset
Kabuuang sagutin
(USD)Hun 2024Y/Y na pagbabago
Cash at mga panandaliang investment
958.84M—
Kabuuang asset
3.27B—
Kabuuang sagutin
574.51M—
Kabuuang equity
2.70B—
Natitirang share
31.05M—
Presyo para makapag-book
0.16—
Return on assets
-15.21%—
Return on capital
-16.72%—
Net change in cash
(USD)Hun 2024Y/Y na pagbabago
Net na kita
-1.59B-721.23%
Cash mula sa mga operasyon
-171.80M-23.68%
Cash mula sa pag-invest
-1.39M51.52%
Cash mula sa financing
932.30M378.34%
Net change in cash
759.12M1,325.15%
Malayang cash flow
-124.26M—
Tungkol
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms. Grail was spun-out from Illumina on June 24, 2024. Their liquid biopsy was launched in June 2021 and is called the Galleri test. Promoted as groundbreaking, the test performed poorly in testing and Grail has subsequently faced discontent and legal action from investors claiming they have been misled about the test's potential. Wikipedia
Itinatag
2015
Website
Mga Empleyado
1,370
Tumuklas pa
Naghanap din ang mga tao ng
Search
I-clear ang paghahanap
Isara ang paghahanap
Mga app ng Google
Pangunahing menu